Other Information.
−Removed: On November 11, 2022, we issued a press release announcing our financial results for the quarter ended September 30, 2022.
−Removed: A copy of the news release is attached to this report as Exhibit 99.1.
+Added: On May 11, 2023, we issued a press release announcing our financial results for the quarter ended March 31, 2023.
+Added: A copy of the news release is attached to this Quarterly Report as Exhibit 99.1.
The press release is being furnished and shall not be deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or incorporated by reference into any filing under the Securities Act of 1933 or the Exchange Act, unless such subsequent filing specifically references the press release.
2 unchanged sentences
Certification of Chief Executive Officer and Chief Financial Officer of the Company in accordance with Section 906 of the Sarbanes-Oxley Act of 2002 (filed herewith).
−Removed: Press Release for Quarter Ended September 30, 2022 (filed herewith).
+Added: Press Release for Quarter Ended March 31, 2022 (filed herewith).
Inline XBRL Instance Document
8 unchanged sentences
Fennec Pharmaceuticals Inc.
−Removed: November 14, 2022
/s/ Rostislav Raykov
2 unchanged sentences
(principal executive officer)
−Removed: November 14, 2022
/s/ Robert Andrade
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.